Long-acting injectable antipsychotics: focus on olanzapine pamoate

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Therapeutics

Background:

• Medication non-adherence is a significant challenge in schizophrenia treatment, leading to adverse outcomes.
• Long-acting injectable (LAI) antipsychotics offer a strategy to improve adherence by ensuring regular dosing.

Purpose of the Study:

• To review the efficacy, safety, and administration considerations of olanzapine pamoate, a new long-acting injectable formulation of olanzapine.
• To assess its role in managing schizophrenia.

Main Methods:

• Review of FDA-approved olanzapine pamoate (olanzapine LAI) data.
• Analysis of clinical trial results regarding efficacy and side effect profiles.
• Evaluation of administration requirements and potential risks.

Main Results:

• Olanzapine LAI demonstrates efficacy in acute and maintenance treatment of schizophrenia at various dosing intervals.
• Its efficacy and side effect profile are comparable to oral olanzapine, with notable metabolic effects.
• A rare but serious risk of post-injection delirium sedation syndrome (PDSS) necessitates specific administration protocols.

Conclusions:

• Olanzapine LAI provides an effective treatment option for schizophrenia patients needing assured medication administration.
• Careful administration by trained personnel with post-injection observation is essential to mitigate PDSS risk.
• Its use is indicated for patients with a history of positive response to oral olanzapine, within appropriate healthcare settings.